Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.

Citigroup has recently reduced Illumina Inc (ILMN) stock to Neutral rating, as announced on December 11, 2024, according to Finviz. Earlier, on November 12, 2024, Morgan Stanley had resumed the stock ...

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Illumina (ILMN – Research Report), with a price target ...

Bernstein analyst Eve Burstein maintained a Hold rating on Illumina (ILMN – Research Report) today. The company’s shares opened today at ...

It is worth considering Illumina (ILMN), which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this genetic testing tools company has ...

Illumina Inc (ILMN) stock saw a modest uptick, ending the day at $144.22 which represents a slight increase of $7.53 or 5.51% from the prior close of $136.69. The stock opened at $137 and touched a ...

Claro Advisors LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 17.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the ...

Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...